Temozolomide

Catalog No.S1237 Synonyms: CCRG81045, NSC 362856

Temozolomide Chemical Structure

Molecular Weight(MW): 194.15

Temozolomide is a monofunctional SN-1 alkylating agent that can modify nitrogen atoms in the DNA ring and the extracyclic oxygen group, chemically converted to MTIC and degrades to methyldiazonium cation, which transfers methyl groups to DNA at physiologic pH. A DNA damage inducer in L-1210 and L-1210/BCNU cells.

Size Price Stock Quantity  
In DMSO USD 64 In stock
USD 70 In stock
USD 170 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 10 Publications

7 Customer Reviews

  • C57BL/6 mice were implanted in the striatum with citrine-GL26-Cherry-HMGB1, which were stably transfected to express the YFP citrine and HMGB1 fused to red fluorescent protein cherry. Fourteen days later, they were treated with saline, Ad-TK+Ad-Flt3L, or Ad-TK+Ad-Flt3L+TMZ (temozolomide). Five days after treatment, the cellular location of cherry-HMGB1 in these cells was assessed by confocal microscopy. Arrows, tumor cells (green) with cytoplasmic HMGB1 (red).

    Clin Cancer Res 2014 20(6), 1555-65. Temozolomide purchased from Selleck.

    D, Scramble (SCR), H82, H865, and H1836 cells were treated with AZD1775 (100 nmol/L) and temozolomide (1 μmol/L) for 24 hours; WEE1 KD cells were treated with just temozolomide (1 μmol/L) for 24 hours. The cells were lysed at 24 hours and subjected to Western blot analysis for phosphorylated WEE1 (pWEE1_S642), pCDC2_Y15 (WEE1 downstream effector), γH2AX (DNA damage marker), PH3 (mitotic marker), cleaved caspase-3 (apoptotic marker), and actin (loading control). E, SCR and WEE1 KD H82, H865, and H1836 cells were treated as described in D and subjected to Western blot analysis for DNA repair markers pATM_S1981, MRE11, RAD51, and E2F1. Actin was used as a loading control.

    Clin Cancer Res, 2017, 23(20):6239-6253. Temozolomide purchased from Selleck.

  • Talazoparib and temozolomide exhibit marked combinatorial efficacy in PDXs. A, Western blot against MGMT by near-infrared imaging in PDX models.

    Clin Cancer Res, 2017, 23(2):523-535. Temozolomide purchased from Selleck.

    J Control Release, 2018, 269:245-257. Temozolomide purchased from Selleck.

  • Viability of U87 cells(A) assessed by the Alamar blue assay, 72 h after transfection with siRNA anti-survivin (siSURV) or with siMUT and/or cell incubation with the chemotherapeutical drugs temozolomide (TMZ) and Bliss interaction index (B) determined for the combined effects on cell viability of survivin silencing plus treatment with each drug. Cells were transfected, for 4 h, with (14Ser)2N5/siRNA/HL complexes and, after an additional period of 20 h, cells were incubated with 400 μM TMZ(A) for 48 h. Results, representative of at least three independent experiments, are expressed as a percentage of the nontreated control cells. Combined treatment (dotted bar) was compared with the single drug treatment (gray bar) (**p < 0.01, ***p < 0.001) and the Bliss interaction index of each combined treatment was compared with the theoretical value expected for an additive effect (1.0) (#p < 0.05, ns, non-significant).

    Eur J Pharm Biopharm, 2016, 104:7-18.. Temozolomide purchased from Selleck.

    Cells were plated and 12 h after plating were treated with MMF (5 µM), FTY720 (50 nM), Temozolomide (TMZ, 3 µM) or in combination as indicated for 12 h. Cell viability was assessed by live / dead assay.

    Cancer Biol Ther, 2014, 15(12):1646-57. Temozolomide purchased from Selleck.

  • Establishment of TMZ-resistant (TR) GBM cell lines. a-d, Evaluation of temozolomide resistance in four glioblastoma cell lines. Cells were cultured in the presence of 5-600 μM of TMZ. A dose-dependent association between the survival rate of cells and TMZ concentration can be observed. Each group was cultured for 24 h in the presence of different concentrations of TMZ, followed by an evaluation of IC50 for TMZ inhibited growth in A172-TR/A172, U118-TR/U118, U251-TR/U251 and U87-TR/U87

    Neurochem Res, 2016, 41(12):3192-3205. Temozolomide purchased from Selleck.

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Temozolomide is a monofunctional SN-1 alkylating agent that can modify nitrogen atoms in the DNA ring and the extracyclic oxygen group, chemically converted to MTIC and degrades to methyldiazonium cation, which transfers methyl groups to DNA at physiologic pH. A DNA damage inducer in L-1210 and L-1210/BCNU cells.
Features Methazolastone is a second-generation alkylating agent.
Targets
DNA replication [1]
(L-1210, L-1210/BCNU cells)
In vitro

Methazolastone causes formation of DNA alkali-labile sites which are present in similar amounts and repaired at a similar rate in L-1210 and L-1210/BCNU cell lines. In L-1210 but not in L-1210/BCNU methazolastone induces an arrest of cells in SL-G2-M phases.[1] Methazolastone sensitivity of both chemo-sensitive and resistant cells (D54-R and U87-R) is enhanced significantly under hyperoxia. Both Methazolastone and hyperoxia are associated with increased phosphorylation of ERK p44/42 MAPK (Erk1/2), but to a lesser extent in D54-R cells, suggesting that Erk1/2 activity may be involved in regulation of hyperoxia and Methazolastone-mediated cell death. Hyperoxia enhances Methazolastone toxicity in GBM cells by induction of apoptosis, possibly via MAPK-related pathways. [2] Methazolastone induces in monocytes the DNA damage response pathways ATM-Chk2 and ATR-Chk1 resulting in p53 activation. [3] Chronic Methazolastone exposure results in acquired Methazolastone-resistance and elevates miR-21 expression. [4] Methazolastone treatment triggers endoplasmic reticula (ER) stress with increased expression of GADD153 and GRP78 proteins, and deceases pro-caspase 12 protein. Methazolastone induces autophagy through mitochondrial damage- and ER stress-dependent mechanisms to protect glioma cells. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kelly NHfORWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;QWnU1QCCq MkjNTWM2OD1zM{muNlDjiIoEsfMAjVUvQTVizszN M17DelI2QTZyMkiy
KellyCis83 NUG0d41lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDWOFghcA>? MmfETWM2OD1{NUGuNFDjiIoEsfMAjVE2Njd3IN88US=> M2nYfFI2QTZyMkiy
SK-N-AS MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDkWnA1QCCq NV\SNWJyUUN3ME2yNlcvPzEkgJpCtgKBkTJ{LkG1JO69VQ>? Mmj0NlU6PjB{OEK=
SK-N-ASCis24 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHrOFghcA>? MmrBTWM2OD12OECuOlDjiIoEsfMAjVExOS5zNTFOwG0> MVSyOVk3ODJ6Mh?=
CHP-212 NX;FWHk3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH25W2Y1QCCq NV\V[5JrUUN3ME23Mlk46oDLwsJihKkxNjZ7IN88US=> MojzNlU6PjB{OEK=
CHP-212Cis100 M2CzdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWq0PEBp NGrEbo1KSzVyPUmuOVXjiIoEsfMAjVAvQDhizszN MV6yOVk3ODJ6Mh?=
U87  MX7GeY5kfGmxbjDBd5NigQ>? MVWxNFAh|ryP NYTodVlDOjRvN{KgbC=> NXriPXBvcW6mdXPld{BF[1JzIHX4dJJme3Orb36= NG\mVYIzPThyOEi2PC=>
LN229 NF71emJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHJNE02OCEQvF2= Mk[zTWM2OD1zNjFOwG0> M4jGVFI2PzVyMkez
TR-LN229 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnse|IxNTVyIN88US=> M122ZmlEPTB;N{eg{txO NWHCUppFOjV5NUCyO|M>
U87  NGfMS4NCeG:ydH;zbZMhSXO|YYm= NWjlSXBpOOLCk{KwNQKBkcL3TR?= MYCyOEBp MX3lcohidmOnczDDVUBqdmS3Y3XkJIFxd3C2b4Ppdy=> NF3aRnIzPTZ6MU[2PC=>
U251MG M2\ER2Fxd3C2b4Ppd{BCe3OjeR?= Mn6zNVAxyqEQvF2= NXW3ZWsyPDhiaB?= NHq0OWJRSlN? NIHOVHdqdmS3Y3XzJIFxd3C2b4Ppdy=> MVqyOVY5ODR4NB?=
U87MG NV73cot7SXCxcITvd4l{KEG|c3H5 NIHBWVUyODEEoN88US=> NYXEWo5wPDhiaB?= NEGwSWlRSlN? NH20ZoRqdmS3Y3XzJIFxd3C2b4Ppdy=> MWqyOVY5ODR4NB?=
U87 MkLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjqdFg2OC1|NUCg{txO MWi0POKhcMLi M2X0S4lvcGmkaYTzJINmdGxiZ4Lve5RpKHOuaXfoeIx6 NEn1RVEzPTV3NEKyNy=>
U118  NV3M[4pQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHQ[5RQPTBvM{WwJO69VQ>? MVe0POKhcMLi MnjybY5pcWKrdIOgZ4VtdCCpcn;3eIghe2yrZ3j0cJk> Ml\wNlU2PTR{MkO=
U87 M17QO2Z2dmO2aX;uJGF{e2G7 MVuyOVAwOzVyIN88US=> M2TZ[VQ5yqCqwrC= NFHIZZBmdmijbnPld{BVVVhvaX7keYNm\CCyLWDLR{1x[W5iZHXjdoVie2V? NYXoe4dCOjV3NUSyNlM>
U118  Mo\MSpVv[3Srb36gRZN{[Xl? M33BPVI2OC9|NUCg{txO NELLTJA1QMLiaNMg NETXSJBmdmijbnPld{BVVVhvaX7keYNm\CCyLWDLR{1x[W5iZHXjdoVie2V? M{m3SlI2PTV2MkKz
U87 NXSyRYNvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLycHIzPTBxM{WwJO69VQ>? MVO0POKhcMLi NELOUWFqdmO{ZXHz[ZMhfGinIIDldoNmdnSjZ3Wgc4Yh[2WubIOgbY4hWyCjbnSgS|IwVcLiY3;0doVifGWmIIfpeIghXE2[ NYnTWXN5OjV3NUSyNlM>
A375 NUSzOo5WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rPXVQ5yqCqwrC= NXLLN4ZMUUN3ME2yOlUh|ryP NXzDV3l6OjV3MkS1OVI>
A2058 NWPYd5hHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDGWmxTPDkEoHlCpC=> NGDNRohKSzVyPUGyJO69VQ>? M{fOeFI2PTJ2NUWy
M238 M3;5WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\1XHJvPDkEoHlCpC=> MWXJR|UxRTRyIN88US=> M3nSZVI2PTJ2NUWy
M249 M{e3cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLHNW01QMLiaNMg NUL3cHdJUUN3ME2yOVQh|ryP NWX3OJJDOjV3MkS1OVI>
M21 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnkUGg{PDkEoHlCpC=> NHT3RXBKSzVyPUKyNUDPxE1? NULLVms3OjV3MkS1OVI>
U251 MXTDfZRwfG:6aYT5JGF{e2G7 MVGyNEDPxE4EoB?= MofrOFjDqGkEoB?= NYnpPIs3emWmdXPl[JMhfGinIIDldoNmdnSjZ3XzJI9nKGOxbH;ubYV{KG[xcn3l[C=> Mo\KNlU1OzR|OEG=
LN229 NF7FUXdEgXSxdH;4bZR6KEG|c3H5 MmHNNlAh|ryPwrC= MlnvOFjDqGkEoB?= MW\y[YR2[2WmczD0bIUheGW{Y3XueIFo\XNib3[gZ49td26rZYOg[o9zdWWm NVTGSXZKOjV2M{SzPFE>
U373MG-LUC M{flbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU[3NkBp NGLjVZVKSzVyPk[wNEDPxE1? NGPw[FEzPTR|MUm1Ny=>
U87  NYPuPHBRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYSyOU0zODBizszN M123dVQ5yqCqwrC= M1\ldYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MljmNlU1ODB5NEW=
U251 NIjtRZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG[y[ZIzPS1{MECg{txO MlqxOFjDqGkEoB?= MmrNbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NHribo4zPTRyMEe0OS=>
U251 M2PlcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV[xNFAuPDByIN88US=> NVnMcoZFPzJxOU[gbC=> MnPzeIhmKGGwdHmtdJJwdGmoZYLheIl3\SCnZn\lZ5Qh[2GwIHLlJIVvcGGwY3XkJIJ6KGexc4P5dI9tKGWwaHHuZ4VlKMLi NV;R[pNQOjV|N{WyO|E>
U373 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LTe|ExOC12MECg{txO MnzwO|IwQTZiaB?= NGjNUZZ1cGViYX70bU1xem:uaX\ldoF1cX[nIHXm[oVkfCClYX6gZoUh\W6qYX7j[YQh[nliZ3;zd5lxd2xiZX7oZY5k\WRiwrC= M4WyZ|I2Ozd3Mkex
U343 NF;DeWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;YNVAxNTRyMDFOwG0> MVy3Nk86PiCq MoG0eIhmKGGwdHmtdJJwdGmoZYLheIl3\SCnZn\lZ5Qh[2GwIHLlJIVvcGGwY3XkJIJ6KGexc4P5dI9tKGWwaHHuZ4VlKMLi Mn\zNlU{PzV{N{G=
U87MG-luc2 NWm2XVVwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWqxNFAuPDByIN88US=> MkPoO|IwQTZiaB?= MYD0bIUh[W62aT3wdo9tcW[ncnH0bZZmKGWoZnXjeEBk[W5iYnWg[Y5p[W6lZXSgZpkh\2:|c4nwc4wh\W6qYX7j[YQhyqB? NUP4NXo5OjV|N{WyO|E>
U87 MXzGeY5kfGmxbjDBd5NigQ>? MofsNlAxKM7:TR?= MWO0PEBp M2\BPIlv[3KnYYPld{BDWkOFMzDtVm5CKGW6cILld5Nqd25? MVqyOVM{Pzd{MR?=
U251 M4XVWWZ2dmO2aX;uJGF{e2G7 MVeyNFAh|ryP MWm0PEBp M4nHTolv[3KnYYPld{BDWkOFMzDtVm5CKGW6cILld5Nqd25? MYmyOVM{Pzd{MR?=
A172 NH7SSVNHfW6ldHnvckBCe3OjeR?= MmrqNlAxKM7:TR?= MW[0PEBp M{jxfYlv[3KnYYPld{BDWkOFMzDtVm5CKGW6cILld5Nqd25? MlrWNlU{Ozd5MkG=
U251 NIfEWJRHfW6ldHnvckBCe3OjeR?= NXzoTpk3OjByIN88US=> M2[zOVQ5KGh? M1m0eolv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBDWkODMTygRnJESTJuIGLBSFUyKGGwZDDGRW5ETDJ? MXiyOVM{Pzd{MR?=
A172 MWLGeY5kfGmxbjDBd5NigQ>? NH\zepAzODBizszN NHTRWVk1QCCq MUXpcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[gRnJESTFuIFLSR2EzNCCUQVS1NUBidmRiRlHOR2Qz M2LwUlI2OzN5N{Kx
U87 NH\1cWlHfW6ldHnvckBCe3OjeR?= MWGyNFAh|ryP NGHS[3UzPC95Mj:xNlAhcA>? NGjRe4tqdmO{ZXHz[ZMh|rOKMlHYJIZw[2liZn;ycYF1cW:wIITpcYUu\GWyZX7k[Y51dHl? M1vRZVI2OzN5N{Kx
U251 MWTGeY5kfGmxbjDBd5NigQ>? M4i1RlIxOCEQvF2= MXKyOE84Oi9zMkCgbC=> M37VRolv[3KnYYPld{DPu0h{QWig[o9kcSCob4LtZZRqd25idHnt[U1l\XCnbnTlcpRtgQ>? MnLCNlU{Ozd5MkG=
A172 NYiy[HF5TnWwY4Tpc44hSXO|YYm= MV2yNFAh|ryP MY[yOE84Oi9zMkCgbC=> NITPd4ZqdmO{ZXHz[ZMh|rOKMlHYJIZw[2liZn;ycYF1cW:wIITpcYUu\GWyZX7k[Y51dHl? NUnQeng3OjV|M{e3NlE>
SNB19V NGjmbGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjwTYVEPyCm MUfEUXNQ NUT5cmp7T0l3ME2zOU44yrFzMjFOwG0> Mo\tNlUzPzd2NEG=
SNB19M NHPRempIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4npO|ch\A>? NXXlbplHTE2VTx?= NELze5pIUTVyPUS2PU46yrF6ODFOwG0> M4PqSlI2Ojd5NESx
SNB19VR MkD5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHUW5Y{PyCm MmjWSG1UVw>? M2q2[2dKPTB;MkiwMlLDuTF6IN88US=> NI\jd|IzPTJ5N{S0NS=>
U373V M3\vfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fVTlch\A>? NVPGPIpRTE2VTx?= MoS5S2k2OD14OD6wxtE{OiEQvF2= NVXNcVNZOjV{N{e0OFE>
U373M MlmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWr6fpVuPyCm MVvEUXNQ MnO0S2k2OD1|NkiuO:KyQDZizszN NWL2[mRyOjV{N{e0OFE>
U373VR MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXO3JIQ> NITDVnNFVVOR MU\HTVUxRTJ6OD64xtE{OyEQvF2= M4fBTVI2Ojd5NESx
U87MG NY\CboNIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3jS|dyPyCm NXfXVVlbTE2VTx?= MXLHTVUxRTN6LkRCtVIxKM7:TR?= NVH3Z45rOjV{N{e0OFE>
HCT116 MlTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUm3JIQ> NXfUVlNqTE2VTx?= MoDCS2k2OD13N{muPeKyOzJizszN M1W2VFI2Ojd5NESx
DLD1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYS3JIQ> MWnEUXNQ NV;zTGZ7T0l3ME21NFEvPMLzOUOg{txO MmDzNlUzPzd2NEG=
MRC5 NXvtWHA4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1WxbVch\A>? NX7YV3NyTE2VTx?= NFnLWVlIUTVyPUS0PU41yrF6IN88US=> NXfmWWxWOjV{N{e0OFE>
SNB19V  MkDzSpVv[3Srb36gRZN{[Xl? NWX1doNWOTByIN88UeKhXE2c M3\kclAuPzJiaB?= MoDCbY5kemWjc3XzJO6{UDKDWDDlfJBz\XO|aX;uJIJmfHenZX6gNVYh[W6mIEeyJIg> MYmyOVI4PzR2MR?=
T98G  NWP6O4FXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnROU8yOC9zNTFOwG0> NH\JXpMzPMLiaB?= MUDpcoR2[2W|IHPlcIwh\GWjdHig[I9{\S2mZYDlcoRmdnSueTDh[pRmeiClb37jc41qfGGwdD30[Y1wgm:ub33p[IUhf2m2aDDOVIU3NVCGVB?= NWDDbYs6OjV{NkK5OlE>
U251  MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vZNFUwOTBxMUWg{txO NWTiTGRjOjUEoHi= NV64XY97cW6mdXPld{Bk\WyuIHTlZZRpKGSxc3Wt[IVx\W6mZX70cJkh[W[2ZYKgZ49v[2:vaYThcpQufGWvb4rvcI9ucWSnIIfpeIghVlCnNj3QSHQ> MWqyOVI3Ojl4MR?=
T98G  MV3GeY5kfGmxbjDBd5NigQ>? MUWxOUDPxE1? NUjI[2tFOjUEoHi= MW\pcoNz\WG|ZYOgSG5CNW[{YXft[Y51[XSrb36gbY4hVlCnNj3QSHQhfHKnYYTl[EBodGmxbXGgZ4VtdHN? MYOyOVI3Ojl4MR?=
U251  M{jlcmZ2dmO2aX;uJGF{e2G7 MXuxOUDPxE1? M2DBb|I1yqCq MnLybY5kemWjc3XzJGRPSS2ocnHncYVvfGG2aX;uJIlvKE6SZU[tVGRVKHS{ZXH0[YQh\2yrb33hJINmdGy| NGnYUXQzPTJ4Mkm2NS=>
U-87 MG NXHsRYd{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVW3NkBp MVnJR|UxRTBwOUOgcW3DqA>? MofWNlUzPDV|M{K=
U-118 MG MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWe0V3pDPzJiaB?= NEfCbXRKSzVyPUGuNFUhdU4EoB?= M2rmcVI2OjR3M{Oy
U87 NVzsS3YzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nKXlI1KGh? Ml\5TWM2OD1{NkCuN|Qh|ryPwrC= M4Lnc|I2OTd|MkOz
U87 GSLCs MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlmwNlQhcA>? MmfNTWM2OD15Nk[uNVEh|ryPwrC= M{fyeFI2OTd|MkOz
U87MG MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXWRVdNPzJiaB?= M2LJVGlEPTB;MUWuOlI2KM7:TdMg MnziNlUxPTB7MUW=
U251 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzNXphROTByLUSwNEDPxE1? M13FVVQ5KGh? Ml\4SG1UVw>? NVzqXY01cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MVWyOFYzOzd|Nh?=
U87 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDYe2oyODBvNECwJO69VQ>? NVPSSVN{PDhiaB?= NID6V2JFVVOR NXTwSJZ{cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NXTUOnloOjR4MkO3N|Y>
MDA-MB-231-br NIDTc5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojnNE0yOCEQvF2= MXK0PEBp Ml\KSG1UVw>? NIfBTnhqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MWOyOFYzOzd|Nh?=
HCC-1937 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWOwMVMxOCEQvF2= NGDB[Ic1QCCq MX\EUXNQ M1P5folvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NVH4PIU{OjR4MkO3N|Y>
MDA-MB-231 M4nqcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DoblAuPDBizszN NEDBS|g1QCCq NF3seVNFVVOR M3TiNIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NWDjcYI2OjR4MkO3N|Y>
MDA-MB-468 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYWwMVUxOCEQvF2= NVXGPWNJPDhiaB?= NWjKdJExTE2VTx?= NXPJWYF1cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MonnNlQ3OjN5M{[=
T47D NIPaR5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXGwMVExOCEQvF2= NYXtZWtNPDhiaB?= NEjlOnJFVVOR MVHpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NHnaXGUzPDZ{M{ezOi=>
MCF7 NUL6boxRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVOxUGd4OC1zMECwJO69VQ>? MYi0PEBp MV3EUXNQ MUXpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NYPwcXFNOjR4MkO3N|Y>
Hs683 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;FNE0yODByIN88US=> MmL1PVYhcA>? MmjmTWM2OD1zMkiuPUDPxE1? MYKyOFQ6PTlyNx?=
U87 NGraenRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;LWY9OOC1zMECwJO69VQ>? NVe0XlVqQTZiaB?= MVnJR|UxRTF6LkS1JO69VQ>? NVHQRnNPOjR2OUW5NFc>
LNZ308 M3G0bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TNT|AuOTByMDFOwG0> MX[5OkBp M1HUOWlEPTB;M{K2Mlch|ryP MWOyOFQ6PTlyNx?=
U87 M4TtVmFxd3C2b4Ppd{BCe3OjeR?= NHrHTm8yODBizszN NHHsTIE1QCCq NV;mOVR6TE2VTx?= M1m3fYlv[3KnYYPld{B1cGViY3HzdIF{\S1|L{egZYN1cX[rdIm= MlzZNlQ1QDF3OE[=
U251  MWHBdI9xfG:|aYOgRZN{[Xl? MYCxNFAh|ryP NIfOSWs1QCCq NEXjNnJFVVOR NEDJb3FqdmO{ZXHz[ZMhfGinIHPhd5Bie2VvMz:3JIFkfGm4aYT5 NGLsOnIzPDR6MUW4Oi=>
U251 NXTpVGt2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLISplCOjRiaB?= MWnJR|UxRTh4LkK55qCKyrIkgJmxMlU5KM7:TR?= M{XQXVI1OzJ4OUW0
U251 NI\JTm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{C0clQ5KGh? M2HKcGlEPTB;N{WuN|TjiIoEsfMAjVEvODJizszN MV:yOFMzPjl3NB?=
U251 MlXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2K1fVczKGh? NXTxb5Q3UUN3ME23Nk41OuLCidMx5qCKOS52NTFOwG0> NETDelUzPDN{Nkm1OC=>
U251 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHP3XWk6PiCq NEP6XmFKSzVyPU[5Mlgz6oDLwsJihKk{NjB2IN88US=> M2fBOVI1OzJ4OUW0
T98G MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHoRWYxNTd3MDFOwG0> M1W0RVczNzl4IHi= MX;pcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? M3zqRlI1OzJ2MEiw
U251-MG NIHBS4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXmwMVgxOCEQvF2= MmnhO|IhcA>? NFLifINqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NYKyOlRpOjRyOUO2N|A>
D54-MG M3PteGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE[1SoMxNThyMDFOwG0> NGnYTpc4OiCq MmDDbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NWj2RVZmOjRyOUO2N|A>
SHG-44 MkfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPVNVAuOjByIN88US=> NEX5S|I6PiCq MXTJR|UxRTlwN{OgxtEhOi5zMjFOwG0> MWiyOFA3PTV4OR?=
U373  NHvTOWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;oNVAuOjByIN88US=> MW[5OkBp MojITWM2OD1zMD6xN{DDuSBzLkCyJO69VQ>? M33TdVI1ODZ3NU[5
HT-29  Mn\zSpVv[3Srb36gRZN{[Xl? Ml7lOVAxKM7:TR?= NWPNXWpGOjRxNEigbC=> M1i5PYVvcGGwY3XzJJRp\SCuZY\lcJMhd2ZizsOtTFJCYMLi M1vMfVI1ODN6ME[4
PC-3  MlS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXRTW4xNTJ3IN88US=> NHzFPYY1QCCq M{TybYlvcGmkaYTzJINmdGxiZ4Lve5RpKHeqaXPoJINidiCkZTDwc5RmdnSrYYTl[EBjgSCueXPvdIVv\Q>? NEO4emYzOzd2NkmzOC=>
PC-3  NWrwdldRSXCxcITvd4l{KEG|c3H5 NYX1e21NOjVizszN M4Ky[FQ5KGh? Mlm4bY5lfWOnczDhdI9xfG:|aYOge4hq[2hiY3HuJIJmKHCxdHXueIlifGWmIHL5JIx6[2:yZX7l M3\qcFI{PzR4OUO0
T98G M3zwbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXK1NE01ODBizszN NVjBd4pKOTR2IHi= NX7Oc2htcW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= NGXqeGczOzdzNUS5PS=>
U87-MG NGHteIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DwZ|ExOCEEtV2= NWnLfHU{PzJiaB?= MkfVbY5pcWKrdIOgZ4VtdCCpcn;3eIghf2irY3igZ4FvKGKnIHXubIFv[2WmIHL5JGdVSg>? NWjYZoJ{OjN4OU[3PFg>
U251-MG Mn;vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjDNVAxKML3TR?= NUjzOXBwPzJiaB?= NXq2c|JncW6qaXLpeJMh[2WubDDndo94fGhid3jpZ4gh[2GwIHLlJIVvcGGwY3XkJIJ6KEeWQh?= NIfvS4wzOzZ7Nke4PC=>
LNT-229 NILxNodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHBVnoyOy1zMECg{txO NXLjVFk4OjRiaB?= M3TJ[YlvcGmkaYTzJINtd26xZ3XubYMhe3W{dnn2ZYwhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M2HKRVI{PjZ5NkOy
T98G M33hSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUexNE04ODBizszN MV:yOEBp NVnveWZlcW6qaXLpeJMh[2yxbn;n[Y5q[yC|dYL2bZZidCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NX;3TmlzOjN4Nke2N|I>
U87  NXTaSmJJTnWwY4Tpc44hSXO|YYm= MVmxNFAhyrWP MYOzJIg> NHjEUWFmdGW4YYTld{B1cGVibHX2[Yx{KG:oIIDDbIsyKGGwZDDwR4hsOg>? MlX1NlM3Pjd2Nkm=
HCT116 M4LWcmZ2dmO2aX;uJGF{e2G7 MUOxNFAhyrWP M3vFU|MhcA>? MoTjbY5lfWOnczD0bIUhS2itMTDQbI9{eGixconsZZRqd25? MVuyN|Y3PzR4OR?=
HCT3-6 M4\FfmZ2dmO2aX;uJGF{e2G7 NHf1VpQyODBiwsXN M4jQUVMhcA>? NX7lOpRbcW6mdXPld{B1cGViQ3jrNUBRcG:|cHjvdplt[XSrb36= M4LOOFI{PjZ5NE[5
U-87  NHzSflBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\tNFYxNTRyIN88US=> M{fNblEzKGR? NVG5NosycW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? Mon6NlM3PDV5Mkm=
U-87  M{jqU2Fxd3C2b4Ppd{BCe3OjeR?= M4LpdlAuPDBizszN NXrk[YREOy94IHS= MmjWbY5lfWOnczDhdI9xfG:|aYOgbY4h[m:2aDDkc5NmNSCjbnSgeIlu\S2mZYDlcoRmdnRibXHucoVz MnTlNlM3PDV5Mkm=
U-87  MYfGeY5kfGmxbjDBd5NigQ>? NXjNbldoOC12MDFOwG0> NHTyV5A{NzZiZB?= M3HUO4lv\HWlZYOgZZV1d3CqYXf5JIlvKGKxdHig[I9{\S1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? M2nIe|I{PjR3N{K5
GB-SCC010 Mny3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHuxPWw1KGR? MUXJR|UxRTJ{NjFOwG0> MX6yN|YyOjd3NR?=
GB-SCC026 M{K5d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXm0JIQ> Ml3vTWM2OD13Mz6xJO69VQ>? NYPDV4FQOjN4MUK3OVU>
GB-SCC028 MmLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjTXHY1KGR? M{O3TWlEPTB;MU[3JO69VQ>? M17kWFI{PjF{N{W1
U87 NIrRWHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;mdXpmPCCm NVjyUI5vUUN3ME20OU4zKM7:TR?= MmLZNlM3OTJ5NUW=
U87 stem cell MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWe0JIQ> MoXpTWM2OD14Nj63JO69VQ>? NVm0W2lSOjN4MUK3OVU>

... Click to View More Cell Line Experimental Data

In vivo After a daily i.p. dose of 40 mg/kg for 5 consecutive days (days 1-5 after tumor transplant), methazolastone increases life-span by 86% in L-1210 and 22% in L-1210/BCNU. In L-1210/BCNU no effect is seen after 100 μM or 200 μM treatment; only 400 μM methazolastone produced an accumulation of cells in premitotic phase but much less than in L-1210. In L-1210/BCNU the maximum accumulation of cells in SL-G2-M is, after 48 hours-72 hours, approximately 30% as compared to 23% in untreated cells. Cells accumulates in SL-G2-M occurred too when L- 1210 leukemia-bearing mice are treated i.v. with methazola stone (40 mg/kg). No such effect is seen on L-1210/BCNU cells from mice given the same drug dose. [1]

Protocol

Cell Research:

[1]

+ Expand
  • Cell lines: L-1210 and L-1210/BCNU cells
  • Concentrations: 0 μM -100 μM
  • Incubation Time: l hours
  • Method:

    L-1210 and L-1210/BCNU cells are seeded at 0.2 × 104 cells/mL and incubated for 24 hours. The cultures are treated with Methazolastone for l hours at 37oC, then washed twice in PBS by centrifugation and resuspended in fresh medium. Controls and treated samples are diluted in fresh medium 1:4 at 48 hours and 1:2 at 96 hours. Using these dilutions cell concentrations throughout the experiments are between 3 × 105 and 8 × 105/mL. Control growth is logarithmic in this range.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: DBA/2 mice with L-1210 and L-1210/BCNU cells
  • Formulation: 95% ethanol
  • Dosages: 40 mg/kg
  • Administration: Administered via i.v.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 38 mg/mL (195.72 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
2mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 194.15
Formula

C6H6N6O2

CAS No. 85622-93-1
Storage powder
in solvent
Synonyms CCRG81045, NSC 362856

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03687034 Not yet recruiting Glioblastoma Leaf Vertical Inc. June 1 2019 Phase 1
NCT03776071 Not yet recruiting Glioblastoma Denovo Biopharma LLC June 2019 Phase 2
NCT03776071 Not yet recruiting Glioblastoma Denovo Biopharma LLC June 2019 Phase 2
NCT03880019 Not yet recruiting Stage III Uterine Corpus Leiomyosarcoma AJCC v8|Stage IIIA Uterine Corpus Leiomyosarcoma AJCC v8|Stage IIIB Uterine Corpus Leiomyosarcoma AJCC v8|Stage IIIC Uterine Corpus Leiomyosarcoma AJCC v8|Stage IV Uterine Corpus Leiomyosarcoma AJCC v8|Stage IVA Uterine Corpus Leiomyosarcoma AJCC v8|Stage IVB Uterine Corpus Leiomyosarcoma AJCC v8 National Cancer Institute (NCI) June 7 2019 Phase 2
NCT03880019 Not yet recruiting Stage III Uterine Corpus Leiomyosarcoma AJCC v8|Stage IIIA Uterine Corpus Leiomyosarcoma AJCC v8|Stage IIIB Uterine Corpus Leiomyosarcoma AJCC v8|Stage IIIC Uterine Corpus Leiomyosarcoma AJCC v8|Stage IV Uterine Corpus Leiomyosarcoma AJCC v8|Stage IVA Uterine Corpus Leiomyosarcoma AJCC v8|Stage IVB Uterine Corpus Leiomyosarcoma AJCC v8 National Cancer Institute (NCI) June 7 2019 Phase 2
NCT03687034 Not yet recruiting Glioblastoma Leaf Vertical Inc. June 1 2019 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products0

Tags: buy Temozolomide | Temozolomide ic50 | Temozolomide price | Temozolomide cost | Temozolomide solubility dmso | Temozolomide purchase | Temozolomide manufacturer | Temozolomide research buy | Temozolomide order | Temozolomide mouse | Temozolomide chemical structure | Temozolomide mw | Temozolomide molecular weight | Temozolomide datasheet | Temozolomide supplier | Temozolomide in vitro | Temozolomide cell line | Temozolomide concentration | Temozolomide nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID